Page last updated: 2024-08-23

etoposide and sirolimus

etoposide has been researched along with sirolimus in 53 studies

Research

Studies (53)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	2 (3.77)	18.2507
2000's	13 (24.53)	29.6817
2010's	34 (64.15)	24.3611
2020's	4 (7.55)	2.80

Authors

Authors	Studies
Bacsó, Z; Cianfriglia, M; Fenyvesi, F; Goda, K; Kappelmayer, J; Lustyik, G; Nagy, H; Szabó, G; Szilasi, M	1
Li, Y; Li, YH; Wang, YH; Yang, L; Yang, SL	1
Cai, W; Hao, Y; Hu, P; Ma, D; Pan, H; Xie, X; Yu, AD; Yu, J; Yuan, J; Zhang, L; Zhu, H	1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A	1
Batista-Gonzalez, A; Brunhofer, G; Fallarero, A; Gopi Mohan, C; Karlsson, D; Shinde, P; Vuorela, P	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Ann, J; Jang, J; Kim, C; Kim, JH; Kim, S; Kim, SE; Kim, WK; Koh, Y; Lee, J; Lee, S; Moon, HS; Tran, PT; Yoon, S	1
Ann, J; Jang, J; Kim, JH; Kim, S; Kim, WK; Koh, Y; Lee, J; Lee, S; Tran, PT; Yoon, I; Yoon, S	1
Ann, J; Cho, D; Kim, JH; Kim, S; Kim, SE; Kim, WK; Lee, J; Lee, S; Yoon, I; Yoon, S; Zuo, D	1
Liu, Y; Xu, Z; Zhao, SJ	1
Bushell, M; McKendrick, L; Morley, SJ	1
Bushell, M; Clemens, MJ; Morley, SJ	1
Cotter, TG; Knox, KA; McGahon, AJ; McKenna, SL; O'Gorman, DM	1
Carroll, M; Thompson, JE; Xu, Q	1
Argentieri, D; Falotico, R; Parry, TJ; Siekierka, J; Tallarida, RJ; Thyagarajan, R	1
Clutter, SD; Fortney, JE; Gibson, LF	1
Cohen, RB; Dahlberg, S; Hidalgo, M; Johnson, DH; Lee, MW; Pandya, KJ; Schiller, JH	1
Marik, PE; Vahid, B	1
Arcaro, A; Dhillon, T; Lane, HA; Lemoine, NR; Marinov, M; Mauri, FA; Pardo, OE; Seckl, MJ; Tan, LT; Zangemeister-Wittke, U; Ziogas, A	1
Akkaya, E; Macaulay, VM; Peak, S; Protheroe, AS; Sullivan, M; Takiguchi, M; Wang, Y; Yuen, JS	1
Farkas, T; Høyer-Hansen, M; Jäättelä, M	1
Bagg, A; Carroll, M; Dierov, JK; Frey, NV; Gewirtz, AM; Goldstein, SC; Hexner, EO; Kasner, MT; Loren, AW; Luger, SM; Nasta, SD; Perl, AE; Porter, DL; Schuster, SJ; Stadtmauer, EA; Swider, CR; Tsai, DE; Vogl, DT	1
Forman, SJ; Karanes, C; Kogut, N; Krishnan, AY; Nademanee, A; Nakamura, R; O'Donnell, M; Palmer, JM; Parker, P; Pullarkat, V; Rodriguez, R; Rosenthal, J; Senitzer, D; Shayani, S; Smith, E; Snyder, D	1
Kiewe, P; Thiel, E	1
Houghton, PJ; Kang, MH; Keshelava, N; Morton, CL; Reynolds, CP; Smith, MA	1
He, XX; Huang, JJ; Huang, Y; Li, ZM; Lin, TY; Tian, Y; Xiao, J	1
Wesierska-Gadek, J	1
Blagosklonny, MV; Leontieva, OV	1
Harada, T; Itamochi, H; Kigawa, J; Naniwa, J; Nonaka, M; Oishi, T; Sato, S; Shimada, M; Terakawa, N; Uegaki, K	1
Abrams, SL; Chappell, WH; Drobot, LB; Franklin, RA; Libra, M; Martelli, AM; McCubrey, JA; Nicoletti, F; Sokolosky, ML; Stadelman, KM; Steelman, LS; Stivala, F	1
Farkas, T; Frankel, LB; Høyer-Hansen, M; Jäättelä, M; Krogh, A; Lees, M; Lund, AH; Wen, J	1
Carroll, M; Kasner, MT; Luger, SM; Perl, AE; Shank, D	1
Levis, M	1
Aurlien, E; Baggerød, E; Bishop, MR; Brinch, L; Dybedal, I; Egeland, T; Fløisand, Y; Fosså, A; Fowler, DH; Gedde-Dahl, T; Heldal, D; Holte, H; Kolstad, A; Kvalheim, G; Lauritzsen, GF; Lehne, G; Tjønnfjord, GE; Torfoss, D	1
Attayan, N; Li, Z; Ramalingam, S; Thiele, CJ; Yan, S	1
Alaggio, R; Bisogno, G; Cecchetto, G; Cheng, L; d'Amore, ES; Dall'Igna, P; Martignoni, G; Sperlì, D	1
Couvelard, A; de Gramont, A; Faivre, S; Hammel, P; Neuzillet, C; Raymond, E; Serova, M; Tijeras-Raballand, A	1
Boddy, N; Burrows, F; Pallis, M; Russell, N; Seedhouse, C; Whittall, A	1
Chen, R; Chen, X; Guo, J; Hu, Z; Liu, Z; Peng, H; Wang, Y; Zhang, H	1
Beck, JT; Besse, B; Camidge, DR; Dimitrijevic, S; Heist, RS; Johnson, BE; Miller, N; Mulatero, C; Papadmitrakopoulou, VA; Petrovic, K; Pylvaenaeinen, I; Schmid, P; Urva, S	1
Assavalapsakul, W; Chung, YH; Johnston, RN; Kaewpiboon, C; Koh, SS; Malilas, W; Moon, J; Phuwapraisirisan, P; Surapinit, S; Tip-Pyang, S	1
Connis, N; Cope, L; Dobromilskaya, I; Gallia, GL; Gardner, EE; Hann, CL; Poirier, JT; Rudin, CM	1
Eberle, C; Guttek, K; Hartig, R; Heiserich, L; Hiemann, R; Lorenz, S; Peters, V; Reddig, A; Reinhold, D; Roggenbuck, D; Sack, U; Schierack, P	1
Kimura, S; Kobayashi-Watanabe, N; Sato, A; Sueoka, E; Sueoka-Aragane, N; Watanabe, T	1
Huang, RC; Kimura, K	1
Akeno, N; Callahan, M; He, D; Kim, RG; Lane, A; Miller, AL; Moulton, JS; Reece, AL; Wikenheiser-Brokamp, KA	1
Carabasi, M; Carroll, M; Filicko-O'Hara, J; Flomenberg, N; Frey, NV; Hexner, EO; Jeschke, GR; Kasner, MT; Loren, AW; Luger, SM; Mangan, JK; Mick, R; Perl, AE; Wagner, JL; Weiss, M	1
Blokland, KEC; Burgess, JK; Grainge, C; Hogaboam, CM; Jaffar, J; Khalil, N; Knight, DA; Mutsaers, SE; Pechkovsky, DV; Prêle, CM; Read, J; Reid, AT; Schuliga, M; Waters, DW; Westall, G	1
Altman, JK; Broun, ER; Carroll, MP; Karp, JE; Kaufmann, SH; Ketterling, RP; Lazarus, HM; Litzow, MR; Luger, SM; Paietta, EM; Pratz, KW; Rowe, JM; Rybka, WB; Tallman, MS; Tun, HW; Wang, XV; Zhang, Y	1
Cash, T; Goldsmith, KC; Katzenstein, HM; Kean, L; MacDonald, TJ; Qayed, M; Suessmuth, Y; Tanos, R; Tighiouart, M; Watkins, B; Wetmore, C	1
Dowlati, A; Finigan, JH; Foster, DG; Gardner, EE; Kern, JA; Kim, J; Mishra, R; Poirier, JT; Rivard, C; Rudin, CM; Tan, AC; Yu, H	1
Bateman, CM; Chi, YY; Cooper, TM; Gaynon, PS; Hutchinson, RJ; Laetsch, TW; Loftus, JP; Malvar, J; Orgel, E; Rheingold, SR; Schafer, ES; Schultz, KR; Silverman, LB; Sposto, R; Sulis, ML; Tasian, SK; Wayne, AS; Whitlock, JA	1
Arancibia, Y; Castro-Guarda, M; Chipón, C; Matamala, C; Morera, FJ; Oyarzo, P; Reyes, A; Salas, M; Vargas, G; Zambrano, A	1

Reviews

5 review(s) available for etoposide and sirolimus

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016
1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships. European journal of medicinal chemistry, 2019, Dec-01, Volume: 183 Topics: Antineoplastic Agents; Humans; Molecular Structure; Neoplasms; Structure-Activity Relationship; Triazoles	2019
Pulmonary complications of novel antineoplastic agents for solid tumors. Chest, 2008, Volume: 133, Issue:2 Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bevacizumab; Deoxycytidine; Doxorubicin; Epirubicin; Etoposide; Everolimus; Gemcitabine; Humans; Lung; Lung Diseases; Mitoxantrone; Neoplasms; Pneumonia; Pyrimidines; Risk Factors; Sirolimus; Teniposide; Trastuzumab	2008
Malignant perivascular epithelioid cell tumor in children: description of a case and review of the literature. Journal of pediatric surgery, 2012, Volume: 47, Issue:6 Topics: Abdominal Neoplasms; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biopsy; Child, Preschool; Combined Modality Therapy; Diagnostic Errors; Etoposide; Female; Humans; Imatinib Mesylate; Intestinal Obstruction; Ligaments; Liver Neoplasms; Neoplasm Recurrence, Local; Peritoneal Neoplasms; Perivascular Epithelioid Cell Neoplasms; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Radiography; Sarcoma, Clear Cell; Sirolimus; X Chromosome Inactivation	2012
Resistance to targeted therapies in pancreatic neuroendocrine tumors (PNETs): molecular basis, preclinical data, and counteracting strategies. Targeted oncology, 2012, Volume: 7, Issue:3 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Drug Resistance, Neoplasm; Etoposide; Everolimus; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Medical Oncology; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sirolimus; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A	2012

Trials

10 trial(s) available for etoposide and sirolimus

Article	Year
A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (E1500) Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2007, Volume: 2, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Remission Induction; Sirolimus; Survival Rate; Treatment Outcome	2007
A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia. Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Nov-01, Volume: 15, Issue:21 Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Administration Schedule; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Melphalan; Middle Aged; Protein Kinases; Recurrence; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases	2009
A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens. Blood, 2010, Feb-04, Volume: 115, Issue:5 Topics: Adolescent; Adult; Busulfan; Child; Cyclophosphamide; Etoposide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Pilot Projects; Radiation Dosage; Siblings; Sirolimus; Survival Analysis; Tacrolimus; Thrombotic Microangiopathies; Tissue Donors; Transplantation Conditioning; Vidarabine; Young Adult	2010
Single-cell pharmacodynamic monitoring of S6 ribosomal protein phosphorylation in AML blasts during a clinical trial combining the mTOR inhibitor sirolimus and intensive chemotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Mar-15, Volume: 18, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Phosphorylation; Pilot Projects; Ribosomal Protein S6; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases	2012
Ultra-short course sirolimus contributes to effective GVHD prophylaxis after reduced-intensity allogeneic hematopoietic cell transplantation. Bone marrow transplantation, 2012, Volume: 47, Issue:12 Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunosuppressive Agents; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisolone; Rituximab; Sirolimus; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Vincristine; Young Adult	2012
A phase Ib dose-escalation study of everolimus combined with cisplatin and etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2014, Volume: 25, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Etoposide; Everolimus; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Sirolimus; Small Cell Lung Carcinoma; Treatment Outcome	2014
Sirolimus enhances remission induction in patients with high risk acute myeloid leukemia and mTORC1 target inhibition. Investigational new drugs, 2018, Volume: 36, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Mechanistic Target of Rapamycin Complex 1; Middle Aged; Mitoxantrone; Phosphorylation; Pilot Projects; Remission Induction; Signal Transduction; Sirolimus	2018
A randomized trial of three novel regimens for recurrent acute myeloid leukemia demonstrates the continuing challenge of treating this difficult disease. American journal of hematology, 2019, Volume: 94, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cytarabine; Disease-Free Survival; Etoposide; Female; Flavonoids; Follow-Up Studies; Gastrointestinal Diseases; Hematologic Diseases; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Piperidines; Recurrence; Remission Induction; Salvage Therapy; Sirolimus; Topotecan; Tumor Lysis Syndrome	2019
A phase I study of sirolimus in combination with metronomic therapy (CHOAnome) in children with recurrent or refractory solid and brain tumors. Pediatric blood & cancer, 2020, Volume: 67, Issue:4 Topics: Administration, Metronomic; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Celecoxib; Child; Child, Preschool; Cyclophosphamide; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Male; Maximum Tolerated Dose; Neoplasms; Sirolimus; Young Adult	2020
Temsirolimus combined with cyclophosphamide and etoposide for pediatric patients with relapsed/refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium trial (TACL 2014-001). Haematologica, 2022, 10-01, Volume: 107, Issue:10 Topics: Adolescent; Alanine Transaminase; Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Etoposide; Humans; MTOR Inhibitors; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphoproteins; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Sirolimus; TOR Serine-Threonine Kinases	2022

Other Studies

38 other study(ies) available for etoposide and sirolimus

Article	Year
Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochemical and biophysical research communications, 2004, Mar-19, Volume: 315, Issue:4 Topics: Adenosine Triphosphatases; Animals; Anti-Bacterial Agents; Antibodies, Monoclonal; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Binding, Competitive; Calcium Channel Blockers; Cyclosporine; Detergents; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Flow Cytometry; Fluoresceins; Humans; Ivermectin; Mice; NIH 3T3 Cells; Substrate Specificity	2004
Modeling K(m) values using electrotopological state: substrates for cytochrome P450 3A4-mediated metabolism. Bioorganic & medicinal chemistry letters, 2005, Sep-15, Volume: 15, Issue:18 Topics: Computational Biology; Cyclohexanols; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Molecular Structure; Principal Component Analysis; Pyrrolizidine Alkaloids; Quantitative Structure-Activity Relationship; Reproducibility of Results; Substrate Specificity; Venlafaxine Hydrochloride	2005
Small molecule regulators of autophagy identified by an image-based high-throughput screen. Proceedings of the National Academy of Sciences of the United States of America, 2007, Nov-27, Volume: 104, Issue:48 Topics: Autophagy; Calcium Channel Blockers; Cell Line, Tumor; Drug Evaluation, Preclinical; Fluspirilene; Glioblastoma; Green Fluorescent Proteins; Humans; Intracellular Membranes; Loperamide; Microtubule-Associated Proteins; Mycotoxins; Peptides; Phagosomes; Phosphatidylinositol Phosphates; Pimozide; Protein Kinases; Recombinant Fusion Proteins; Sirolimus; Small Molecule Libraries; TOR Serine-Threonine Kinases; Trifluoperazine; Zinc Fingers	2007
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chemical research in toxicology, 2010, Volume: 23, Issue:1 Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship	2010
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine. Bioorganic & medicinal chemistry, 2012, Nov-15, Volume: 20, Issue:22 Topics: Acetylcholinesterase; Amyloid beta-Peptides; Benzophenanthridines; Binding Sites; Butyrylcholinesterase; Catalytic Domain; Cholinesterase Inhibitors; Humans; Isoquinolines; Kinetics; Molecular Docking Simulation; Structure-Activity Relationship	2012
Discovery of Leucyladenylate Sulfamates as Novel Leucyl-tRNA Synthetase (LRS)-Targeted Mammalian Target of Rapamycin Complex 1 (mTORC1) Inhibitors. Journal of medicinal chemistry, 2016, 11-23, Volume: 59, Issue:22 Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Leucine; Leucine-tRNA Ligase; Mechanistic Target of Rapamycin Complex 1; Molecular Structure; Multiprotein Complexes; Structure-Activity Relationship; TOR Serine-Threonine Kinases	2016
Discovery of simplified leucyladenylate sulfamates as novel leucyl-tRNA synthetase (LRS)-targeted mammalian target of rapamycin complex 1 (mTORC1) inhibitors. Bioorganic & medicinal chemistry, 2017, 08-01, Volume: 25, Issue:15 Topics: Cell Line, Tumor; Drug Discovery; Drug Screening Assays, Antitumor; HEK293 Cells; Humans; Leucine-tRNA Ligase; Mass Spectrometry; Mechanistic Target of Rapamycin Complex 1; Phosphorylation; Proton Magnetic Resonance Spectroscopy; Ribosomal Protein S6 Kinases; Sulfonic Acids	2017
Discovery of novel leucyladenylate sulfamate surrogates as leucyl-tRNA synthetase (LRS)-targeted mammalian target of rapamycin complex 1 (mTORC1) inhibitors. Bioorganic & medicinal chemistry, 2018, 08-07, Volume: 26, Issue:14 Topics: Antineoplastic Agents; Cell Line; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Leucine; Leucine-tRNA Ligase; Mechanistic Target of Rapamycin Complex 1; Molecular Structure; Structure-Activity Relationship	2018
Cleavage of translation initiation factor 4G (eIF4G) during anti-Fas IgM-induced apoptosis does not require signalling through the p38 mitogen-activated protein (MAP) kinase. FEBS letters, 1998, Oct-30, Volume: 438, Issue:1-2 Topics: Amino Acid Chloromethyl Ketones; Apoptosis; Arsenites; Calcium-Calmodulin-Dependent Protein Kinases; Caspase Inhibitors; Cell Survival; Etoposide; Eukaryotic Initiation Factor-4E; Eukaryotic Initiation Factor-4G; fas Receptor; Humans; Imidazoles; Immunoglobulin M; Jurkat Cells; Mitogen-Activated Protein Kinases; p38 Mitogen-Activated Protein Kinases; Peptide Initiation Factors; Phosphorylation; Poly(A)-Binding Proteins; Protein Biosynthesis; Pyridines; RNA-Binding Proteins; Signal Transduction; Sirolimus	1998
Degradation of eukaryotic polypeptide chain initiation factor (eIF) 4G in response to induction of apoptosis in human lymphoma cell lines. Oncogene, 1998, Dec-03, Volume: 17, Issue:22 Topics: Amino Acid Chloromethyl Ketones; Antibodies; Apoptosis; Caspase Inhibitors; Caspases; Culture Media, Serum-Free; Cycloheximide; Etoposide; Eukaryotic Initiation Factor-4E; fas Receptor; Half-Life; Humans; Jurkat Cells; Lymphoma; Molecular Weight; Neoplasm Proteins; Oligopeptides; Peptide Initiation Factors; Poly(A)-Binding Proteins; Poly(ADP-ribose) Polymerases; Protein Synthesis Inhibitors; RNA-Binding Proteins; Sirolimus; Tumor Cells, Cultured	1998
Sensitisation of HL60 human leukaemic cells to cytotoxic drug-induced apoptosis by inhibition of PI3-kinase survival signals. Leukemia, 2000, Volume: 14, Issue:4 Topics: Androstadienes; Antineoplastic Agents; Apigenin; Apoptosis; bcl-Associated Death Protein; bcl-X Protein; Camptothecin; Carrier Proteins; Cell Survival; Chromones; Cycloheximide; Dactinomycin; Dimerization; Doxorubicin; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Flavonoids; Genes, bcl-2; HL-60 Cells; Humans; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Mitoxantrone; Morpholines; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Sirolimus; Wortmannin	2000
mTOR regulates cell survival after etoposide treatment in primary AML cells. Blood, 2005, Dec-15, Volume: 106, Issue:13 Topics: Animals; Cell Survival; Culture Media; Etoposide; Humans; Leukemia, Myeloid, Acute; Mice; Protein Kinases; Sirolimus; Stem Cells; Time Factors; TOR Serine-Threonine Kinases; Tumor Cells, Cultured	2005
Effects of drug combinations on smooth muscle cell proliferation: an isobolographic analysis. European journal of pharmacology, 2006, Feb-17, Volume: 532, Issue:1-2 Topics: Algorithms; Cell Proliferation; Cell Survival; Cells, Cultured; Cladribine; Coronary Vessels; Dose-Response Relationship, Drug; Drug Synergism; Etoposide; Growth Inhibitors; Humans; Myocytes, Smooth Muscle; Sirolimus; Topotecan	2006
Chemotherapy disrupts activity of translational regulatory proteins in bone marrow stromal cells. Experimental hematology, 2006, Volume: 34, Issue:11 Topics: Adaptor Proteins, Signal Transducing; Animals; Antimetabolites, Antineoplastic; Bone Marrow Cells; Cell Cycle Proteins; Cell Line; Cyclophosphamide; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Etoposide; Humans; Matrix Metalloproteinase 2; Melphalan; Mice; Phosphatidylinositol 3-Kinases; Phosphoproteins; Phosphorylation; Protein Kinases; Protein Serine-Threonine Kinases; Ribosomal Protein S6; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; Sirolimus; Stromal Cells; Structure-Activity Relationship; TOR Serine-Threonine Kinases	2006
AKT/mTOR pathway activation and BCL-2 family proteins modulate the sensitivity of human small cell lung cancer cells to RAD001. Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Feb-15, Volume: 15, Issue:4 Topics: Animals; Antineoplastic Agents; Carcinoma, Small Cell; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Drug Resistance, Neoplasm; Etoposide; Everolimus; Humans; Lung Neoplasms; Mice; Protein Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Sirolimus; Stem Cell Factor; TOR Serine-Threonine Kinases	2009
Validation of the type 1 insulin-like growth factor receptor as a therapeutic target in renal cancer. Molecular cancer therapeutics, 2009, Volume: 8, Issue:6 Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Survival; Cisplatin; Dose-Response Relationship, Drug; Etoposide; Female; Fluorouracil; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunoblotting; Kidney Neoplasms; Mice; Mice, Inbred BALB C; Mice, SCID; Receptor, IGF Type 1; RNA, Small Interfering; Sirolimus; Transfection; Von Hippel-Lindau Tumor Suppressor Protein; Xenograft Model Antitumor Assays	2009
Identification of novel autophagy regulators by a luciferase-based assay for the kinetics of autophagic flux. Autophagy, 2009, Volume: 5, Issue:7 Topics: Animals; Anti-Bacterial Agents; Antineoplastic Agents, Phytogenic; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Biological Assay; Cells, Cultured; Enzyme Inhibitors; Etoposide; Fibroblasts; Genes, Reporter; Humans; Luciferases; Membrane Proteins; Mice; Microtubule-Associated Proteins; Recombinant Fusion Proteins; RNA, Small Interfering; Sirolimus	2009
Impressive response to temsirolimus in a patient with chemotherapy refractory diffuse large B-cell non-Hodgkin's lymphoma. Annals of hematology, 2011, Volume: 90, Issue:1 Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Prednisolone; Remission Induction; Sirolimus; Tongue Neoplasms; Treatment Failure; Treatment Outcome; Vincristine	2011
National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing. Pediatric blood & cancer, 2011, Volume: 56, Issue:2 Topics: Antineoplastic Agents; Cell Line, Tumor; Child; Drug Screening Assays, Antitumor; Etoposide; Humans; Melphalan; National Cancer Institute (U.S.); Sirolimus; United States; Vincristine	2011
Schedule-dependent inhibition of T-cell lymphoma cells by cotreatment with the mTOR inhibitor everolimus and anticancer drugs. Investigational new drugs, 2012, Volume: 30, Issue:1 Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Proliferation; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Etoposide; Everolimus; Humans; Jurkat Cells; Lymphoma, T-Cell; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Pyrazines; Sirolimus; Time Factors; TOR Serine-Threonine Kinases; Vincristine	2012
mTOR and its link to the picture of Dorian Gray - re-activation of mTOR promotes aging. Aging, 2010, Volume: 2, Issue:12 Topics: Animals; Cell Cycle; Cell Proliferation; Cell Shape; Cellular Senescence; DNA Damage; Doxorubicin; Enzyme Activation; Etoposide; Humans; Imidazoles; Piperazines; Protein Kinase Inhibitors; Serum; Sirolimus; Time Factors; TOR Serine-Threonine Kinases; Tumor Suppressor Protein p53; Up-Regulation	2010
DNA damaging agents and p53 do not cause senescence in quiescent cells, while consecutive re-activation of mTOR is associated with conversion to senescence. Aging, 2010, Volume: 2, Issue:12 Topics: Cell Cycle; Cell Line; Cell Proliferation; Cell Shape; Cellular Senescence; DNA Damage; Doxorubicin; Enzyme Activation; Etoposide; Humans; Imidazoles; Neoplasms; Piperazines; Protein Kinase Inhibitors; Retinal Pigment Epithelium; Serum; Sirolimus; Time Factors; TOR Serine-Threonine Kinases; Tumor Suppressor Protein p53; Up-Regulation	2010
Inhibiting the mTOR pathway synergistically enhances cytotoxicity in ovarian cancer cells induced by etoposide through upregulation of c-Jun. Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Jul-15, Volume: 17, Issue:14 Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Etoposide; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Ovarian Neoplasms; Proto-Oncogene Proteins c-jun; Signal Transduction; Sirolimus; Survival Analysis; TOR Serine-Threonine Kinases; Up-Regulation; Xenograft Model Antitumor Assays	2011
Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapy. Oncotarget, 2011, Volume: 2, Issue:7 Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Molecular Targeted Therapy; Proto-Oncogene Proteins c-akt; Signal Transduction; Sirolimus; Tamoxifen; TOR Serine-Threonine Kinases	2011
microRNA-101 is a potent inhibitor of autophagy. The EMBO journal, 2011, Sep-13, Volume: 30, Issue:22 Topics: Autophagy; Autophagy-Related Proteins; Breast Neoplasms; Cell Line, Tumor; Cysteine Endopeptidases; Etoposide; Female; Gene Expression Profiling; Gene Expression Regulation; Humans; MicroRNAs; Oligonucleotide Array Sequence Analysis; rab5 GTP-Binding Proteins; RNA Interference; RNA, Small Interfering; Sirolimus; Stathmin; Tamoxifen	2011
Phospho-specific flow: fixating on the target. Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Mar-15, Volume: 18, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Ribosomal Protein S6; Sirolimus; TOR Serine-Threonine Kinases	2012
Combination of an allosteric Akt Inhibitor MK-2206 with etoposide or rapamycin enhances the antitumor growth effect in neuroblastoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Jul-01, Volume: 18, Issue:13 Topics: Allosteric Regulation; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Etoposide; Female; Heterocyclic Compounds, 3-Ring; Humans; Inhibitory Concentration 50; Mice; Mice, Nude; Neuroblastoma; Phosphorylation; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Sirolimus; Tumor Burden; Xenograft Model Antitumor Assays	2012
Efficacy of RNA polymerase II inhibitors in targeting dormant leukaemia cells. BMC pharmacology & toxicology, 2013, Jun-15, Volume: 14 Topics: Acute Disease; Adenine Nucleotides; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Azacitidine; Cell Line, Tumor; Cell Survival; Clofarabine; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Enzyme Inhibitors; Etoposide; Flavonoids; Heterocyclic Compounds, 4 or More Rings; Humans; Leukemia, Myeloid; Piperidines; Purines; RNA Polymerase II; RNA, Neoplasm; Roscovitine; Sirolimus; TOR Serine-Threonine Kinases	2013
MTOR inhibition attenuates DNA damage and apoptosis through autophagy-mediated suppression of CREB1. Autophagy, 2013, Volume: 9, Issue:12 Topics: Animals; Apoptosis; Autophagy; Cells, Cultured; Cyclic AMP Response Element-Binding Protein; DNA Damage; Down-Regulation; Drug Resistance, Neoplasm; Etoposide; Humans; MCF-7 Cells; Mice; Mice, Transgenic; Rats; Sirolimus; TOR Serine-Threonine Kinases	2013
Feroniellin A-induced autophagy causes apoptosis in multidrug-resistant human A549 lung cancer cells. International journal of oncology, 2014, Volume: 44, Issue:4 Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; ATP Binding Cassette Transporter, Subfamily B; Autophagy; Beclin-1; Cell Line, Tumor; Coumarins; Drug Resistance, Neoplasm; Etoposide; Furans; Glycosides; Humans; Lung Neoplasms; Membrane Proteins; Microfilament Proteins; Nitriles; Promoter Regions, Genetic; RNA Interference; RNA, Small Interfering; Sirolimus; Sulfones; Transcription Factor RelA; Transcription, Genetic	2014
Rapamycin rescues ABT-737 efficacy in small cell lung cancer. Cancer research, 2014, May-15, Volume: 74, Issue:10 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biphenyl Compounds; Cell Line, Tumor; Drug Synergism; Etoposide; Female; Humans; Lung Neoplasms; Mice; Mice, SCID; Nitrophenols; Piperazines; Proto-Oncogene Proteins c-bcl-2; Random Allocation; Sirolimus; Small Cell Lung Carcinoma; Sulfonamides; Xenograft Model Antitumor Assays	2014
Assessment of modulated cytostatic drug resistance by automated γH2AX analysis. Cytometry. Part A : the journal of the International Society for Analytical Cytology, 2015, Volume: 87, Issue:8 Topics: Adult; Cyclosporine; Cytostatic Agents; DNA; DNA Breaks, Double-Stranded; Drug Resistance, Multiple; Etoposide; Female; Histones; Humans; Leukocytes, Mononuclear; Male; Microscopy, Fluorescence; Sirolimus; Young Adult	2015
Torin2 Potentiates Anticancer Effects on Adult T-Cell Leukemia/Lymphoma by Inhibiting Mammalian Target of Rapamycin. Anticancer research, 2016, Volume: 36, Issue:1 Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Etoposide; G1 Phase Cell Cycle Checkpoints; Humans; Leukemia-Lymphoma, Adult T-Cell; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Multiprotein Complexes; Naphthyridines; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases	2016
Tetra-O-Methyl Nordihydroguaiaretic Acid Broadly Suppresses Cancer Metabolism and Synergistically Induces Strong Anticancer Activity in Combination with Etoposide, Rapamycin and UCN-01. PloS one, 2016, Volume: 11, Issue:2 Topics: Antineoplastic Agents; Autophagy; Carbohydrate Metabolism; Caspase 7; Cell Line, Tumor; Down-Regulation; Drug Synergism; Energy Metabolism; Etoposide; Glutathione; Humans; Lipid Metabolism; Male; Masoprocol; Metabolic Networks and Pathways; Metabolome; Neoplasms; Oxidative Stress; Reactive Oxygen Species; Sirolimus; Staurosporine	2016
TRP53 Mutants Drive Neuroendocrine Lung Cancer Through Loss-of-Function Mechanisms with Gain-of-Function Effects on Chemotherapy Response. Molecular cancer therapeutics, 2017, Volume: 16, Issue:12 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Models, Animal; Disease Progression; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred C57BL; Neuroendocrine Tumors; Sirolimus; Small Cell Lung Carcinoma; Tumor Suppressor Protein p53	2017
Mitochondrial dysfunction contributes to the senescent phenotype of IPF lung fibroblasts. Journal of cellular and molecular medicine, 2018, Volume: 22, Issue:12 Topics: Acetylcysteine; Biomarkers; Cellular Senescence; Cyclic N-Oxides; Down-Regulation; Etoposide; Fibroblasts; Humans; Idiopathic Pulmonary Fibrosis; Lung; Mitochondria; Myofibroblasts; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Rotenone; Sirolimus	2018
Role of mTOR As an Essential Kinase in SCLC. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2020, Volume: 15, Issue:9 Topics: Cisplatin; Etoposide; Humans; Lung Neoplasms; Sirolimus; Small Cell Lung Carcinoma; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays	2020
Metabolic changes induced by DNA damage in Ramos cells: exploring the role of mTORC1 complex. FEBS open bio, 2022, Volume: 12, Issue:8 Topics: DNA Damage; Etoposide; Mechanistic Target of Rapamycin Complex 1; Sirolimus; TOR Serine-Threonine Kinases	2022